Real-world prognosis of eyes with diabetic macular oedema receiving treatment with vascular endothelial growth factor (VEGF) inhibitors

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:

To assess one- to five-year visual prognosis of eyes receiving intravitreal VEGF inhibitor treatments for DMO in routine clinical practice.

Investigation of sources of heterogeneity between studies

We will assess the source of heterogeneity in the outcome measures between studies.

This is a protocol.